Vanguard Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $5.04M | Buy |
12,000,383
+385,233
| +3% | +$204K | ﹤0.01% | 3250 |
|
|
2025
Q3 | $7.82M | Buy |
11,615,150
+2,240,422
| +24% | +$1.21M | ﹤0.01% | 3109 |
|
|
2025
Q2 | $5.07M | Hold |
9,374,728
| – | – | ﹤0.01% | 3212 |
|
|
2025
Q1 | $6.15M | Hold |
9,374,728
| – | – | ﹤0.01% | 3093 |
|
|
2024
Q4 | $9.56M | Sell |
9,374,728
-223,049
| -2% | -$408K | ﹤0.01% | 2983 |
|
|
2024
Q3 | $8.31M | Sell |
9,597,777
-2,300,640
| -19% | -$1.69M | ﹤0.01% | 3048 |
|
|
2024
Q2 | $4.26M | Sell |
11,898,417
-301,951
| -2% | -$163K | ﹤0.01% | 3321 |
|
|
2024
Q1 | $8.18M | Sell |
12,200,368
-398,761
| -3% | -$289K | ﹤0.01% | 3074 |
|
|
2023
Q4 | $6.85M | Buy |
12,599,129
+68,884
| +0.5% | +$31.8K | ﹤0.01% | 3151 |
|
|
2023
Q3 | $7.52M | Buy |
12,530,245
+131,833
| +1% | +$141K | ﹤0.01% | 3058 |
|
|
2023
Q2 | $16.1M | Sell |
12,398,412
-1,982,497
| -14% | -$2.71M | ﹤0.01% | 2682 |
|
|
2023
Q1 | $25.3M | Buy |
14,380,909
+335,300
| +2% | +$957K | ﹤0.01% | 2489 |
|
|
2022
Q4 | $44.1M | Buy |
14,045,609
+1,314,500
| +10% | +$5.1M | ﹤0.01% | 2245 |
|
|
2022
Q3 | $62.4M | Buy |
12,731,109
+1,205,951
| +10% | +$6.19M | ﹤0.01% | 2073 |
|
|
2022
Q2 | $47.7M | Buy |
11,525,158
+1,389,297
| +14% | +$6.01M | ﹤0.01% | 2214 |
|
|
2022
Q1 | $58.9M | Buy |
10,135,861
+795,306
| +9% | +$4.73M | ﹤0.01% | 2223 |
|
|
2021
Q4 | $70.1M | Buy |
9,340,555
+145,220
| +2% | +$1.26M | ﹤0.01% | 2168 |
|
|
2021
Q3 | $82.9M | Buy |
9,195,335
+90,077
| +1% | +$890K | ﹤0.01% | 2082 |
|
|
2021
Q2 | $109M | Sell |
9,105,258
-17,059
| -0.2% | -$193K | ﹤0.01% | 1958 |
|
|
2021
Q1 | $114M | Buy |
9,122,317
+668,659
| +8% | +$9.01M | ﹤0.01% | 1877 |
|
|
2020
Q4 | $132M | Buy |
8,453,658
+327,099
| +4% | +$3.83M | ﹤0.01% | 1697 |
|
|
2020
Q3 | $76.8M | Sell |
8,126,559
-345,336
| -4% | -$3.74M | ﹤0.01% | 1812 |
|
|
2020
Q2 | $75.9M | Sell |
8,471,895
-82,743
| -1% | -$768K | ﹤0.01% | 1799 |
|
|
2020
Q1 | $54.5M | Buy |
8,554,638
+66,134
| +0.8% | +$491K | ﹤0.01% | 1837 |
|
|
2019
Q4 | $71M | Buy |
8,488,504
+153,398
| +2% | +$1.41M | ﹤0.01% | 1936 |
|
|
2019
Q3 | $75.4M | Buy |
8,335,106
+25,945
| +0.3% | +$291K | ﹤0.01% | 1870 |
|
|
2019
Q2 | $89.5M | Buy |
8,309,161
+596,573
| +8% | +$6.34M | ﹤0.01% | 1808 |
|
|
2019
Q1 | $73.6M | Buy |
7,712,588
+117,336
| +2% | +$1.2M | ﹤0.01% | 1889 |
|
|
2018
Q4 | $87.2M | Buy |
7,595,252
+117,561
| +2% | +$1.46M | ﹤0.01% | 1753 |
|
|
2018
Q3 | $127M | Sell |
7,477,691
-686,132
| -8% | -$10.4M | 0.01% | 1682 |
|
|
2018
Q2 | $116M | Buy |
8,163,823
+1,220,399
| +18% | +$20.3M | ﹤0.01% | 1701 |
|
|
2018
Q1 | $132M | Buy |
6,943,424
+2,463,455
| +55% | +$52.7M | 0.01% | 1558 |
|
|
2017
Q4 | $73.5M | Buy |
4,479,969
+548,015
| +14% | +$8.15M | ﹤0.01% | 1869 |
|
|
2017
Q3 | $59M | Buy |
3,931,954
+460,273
| +13% | +$5.09M | ﹤0.01% | 1959 |
|
|
2017
Q2 | $30.6M | Buy |
3,471,681
+384,031
| +12% | +$2.46M | ﹤0.01% | 2265 |
|
|
2017
Q1 | $16.1M | Buy |
3,087,650
+239,544
| +8% | +$961K | ﹤0.01% | 2536 |
|
|
2016
Q4 | $8.69M | Buy |
2,848,106
+122,362
| +4% | +$446K | ﹤0.01% | 2811 |
|
|
2016
Q3 | $12.6M | Buy |
2,725,744
+31,351
| +1% | +$159K | ﹤0.01% | 2576 |
|
|
2016
Q2 | $15.6M | Buy |
2,694,393
+234,286
| +10% | +$1.49M | ﹤0.01% | 2438 |
|
|
2016
Q1 | $14.9M | Sell |
2,460,107
-62,738
| -2% | -$377K | ﹤0.01% | 2415 |
|
|
2015
Q4 | $23M | Buy |
2,522,845
+45,666
| +2% | +$352K | ﹤0.01% | 2248 |
|
|
2015
Q3 | $14M | Buy |
2,477,179
+145,445
| +6% | +$1.2M | ﹤0.01% | 2440 |
|
|
2015
Q2 | $25.9M | Buy |
2,331,734
+71,937
| +3% | +$927K | ﹤0.01% | 2245 |
|
|
2015
Q1 | $35.4M | Buy |
2,259,797
+114,411
| +5% | +$1.77M | ﹤0.01% | 2080 |
|
|
2014
Q4 | $32.6M | Buy |
2,145,386
+101,588
| +5% | +$1.23M | ﹤0.01% | 2032 |
|
|
2014
Q3 | $22M | Buy |
2,043,798
+27,317
| +1% | +$357K | ﹤0.01% | 2166 |
|
|
2014
Q2 | $30.8M | Buy |
2,016,481
+57,859
| +3% | +$832K | ﹤0.01% | 2064 |
|
|
2014
Q1 | $35.4M | Buy |
1,958,622
+184,871
| +10% | +$3.56M | ﹤0.01% | 1982 |
|
|
2013
Q4 | $24.6M | Buy |
1,773,751
+101,394
| +6% | +$1.17M | ﹤0.01% | 2094 |
|
|
2013
Q3 | $17.5M | Buy |
1,672,357
+260,599
| +18% | +$2.59M | ﹤0.01% | 2159 |
|
|
2013
Q2 | $11M | Buy |
+1,411,758
| New | +$12.3M | ﹤0.01% | 2291 |
|
Other funds holding SGMO
WA
Vanguard Group's SGMO Position: Q4 2025 in Review
Vanguard Group increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 3.3% in Q4 2025, buying an estimated $204K and bringing the position to 12,000,383 shares worth $5.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3250.
Vanguard Group first reported a position in SGMO in Q2 2013 and has held it in 51 quarters since. The position peaked at $132M in Q1 2018. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.
- Vanguard Group held 12,000,383 shares of SANGAMO THERAPEUTICS INC worth $5.04M as of Q4 2025.
- Vanguard Group bought 385,233 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $204K.
- SANGAMO THERAPEUTICS INC made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3250 holding.
- Vanguard Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's SANGAMO THERAPEUTICS INC position peaked at $132M in Q1 2018.
- 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.